Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Tuesday. The firm issued a buy rating and a $7.00 target price on the biotechnology company’s stock.

A number of other analysts have also issued reports on CLLS. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st. Clear Str raised shares of Cellectis to a “strong-buy” rating in a research report on Tuesday, December 23rd. Finally, Wells Fargo & Company restated a “positive” rating and issued a $4.00 target price on shares of Cellectis in a report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cellectis presently has a consensus rating of “Moderate Buy” and an average target price of $6.33.

Cellectis Price Performance

Shares of CLLS opened at $3.88 on Tuesday. Cellectis has a fifty-two week low of $1.10 and a fifty-two week high of $5.48. The stock has a fifty day moving average of $4.26 and a two-hundred day moving average of $3.78. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.63.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after buying an additional 3,284,409 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Cellectis during the 4th quarter worth $15,385,000. Citadel Advisors LLC acquired a new stake in Cellectis in the 3rd quarter valued at $633,000. Marshall Wace LLP increased its holdings in Cellectis by 1,610.3% in the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares during the period. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.